In this Healio video perspective, Carly Levy, MD, FAAP, FAAHPM, shares her advice for physicians to cope with tough days at ...
Takeda is tapping out of the cell therapy arena as part of a "strategic portfolio reprioritization," with 137 roles at the drugmaker's Massachusetts R&D site affected. The company is seeking a partner ...
Imber-Black (1981; Dickerson, 2024), formerly Coppersmith, successfully reframed some behavior problems not as psychopathology or delinquency but as immaturity. Her article, subtitled "He's Not Bad, ...
both alone and in couples counseling. It helped a little, but the same old patterns kept returning. "It just didn't stick," he says. "I'd fall right back into my old ways." So, he tried something new.
Therapists treating Medicaid enrollees in Colorado will have to get the state’s authorization to conduct more than 24 sessions with an individual patient in a year, as the department overseeing the ...
Hosted on MSN
NEET UG Counselling 2025: Round 3 Registration Begins, Check Important Dates, Top Medical Colleges
NEET UG Round 3 Registration 2025: Medical Counselling Committee (MCC) has started the registration process for Round 3 NEET UG counselling 2025 of All India Quota/Deemed and Central universities.
This is not the place to analyze the details of former FBI Director James Comey’s indictment because we don’t know what those details are. Prosecutors will soon have to come up with a bill of ...
Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better treatment ...
Preliminary results from a small trial offer the clearest evidence yet that the brain disease’s progression can be slowed. A one-time gene therapy can markedly slow the progression of Huntington’s ...
An experimental gene therapy has become the first treatment to successfully slow the progression of Huntington’s disease. While the findings are still preliminary, the approach could be a major ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results